Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunity Strong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestiture Conference call today at 5:00 p.m. ET / 2:00 p.m.